NextBreath is a free, biannual virtual event that provides support and connection for people with CF and their family members who are living with advanced disease or navigating through the stages of the transplant process.
Site Search
Breadth of expertise in business, philanthropy, community engagement, and venture capital to help advance Foundation’s mission
Proposed policies would impose significant barriers and add burden for people with CF
Groups urging need for revitalizing antimicrobial development call for passage of the bill this year
The U.S. Food and Drug Administration approved Kalydeco® (ivacaftor) for infants as young as 1 month who have at least one copy of 97 mutations that have proven to be responsive to Kalydeco.
Medicaid beneficiaries are encouraged to update their information with Medicaid to ensure continued coverage.
The Cystic Fibrosis Foundation is providing additional funds to TB Alliance to advance the development of a compound that could be used to treat infections caused by nontuberculous mycobacteria.
The Cystic Fibrosis Foundation is providing additional funding to Arcturus Therapeutics to develop an inhaled messenger RNA therapy for CF that provides lung cells with the correct instructions to make functional cystic fibrosis transmembrane conductance regulator protein. The funding brings our total commitment to Arcturus to approximately $25 million.
Centering the patient experience is the only way to successfully reform pharmacy benefit manager practices